公开(公告)号：US11643452B2

公开(公告)日：2023-05-09

申请号：US17341098

申请日：2021-06-07

申请人： ImmunityBio, Inc.

发明人： Laurent H. Boissel ,  Hans G. Klingemann ,  Abhijit Dandapat ,  Himani Chinnapen

IPC分类号： C07K14/735 ,  A61K38/17 ,  C07K16/28 ,  A61K39/395 ,  C07K14/55 ,  C07K14/54 ,  C12N5/0783 ,  A61P35/00 ,  A61K35/17 ,  A61K38/20 ,  A61K45/06 ,  C07K14/705 ,  C07K16/32 ,  A61K39/00

CPC分类号： C07K14/70535 ,  A61K35/17 ,  A61K38/1774 ,  A61K38/2013 ,  A61K38/2086 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/32 ,  C12N5/0646 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2510/00

摘要： Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.

公开(公告)号：US20240016849A1

公开(公告)日：2024-01-18

申请号：US18463907

申请日：2023-09-08

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Hans G Klingemann ,  Laurent H Boissel ,  Himani Chinnapen ,  Abhijit Dandapat

IPC分类号： A61K35/17 ,  A61K38/17

CPC分类号： A61K35/17 ,  A61K38/1774

摘要： The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and/or TAM. The methods and compositions are useful for treating a disease associated with MDSC and/or TAM infiltration into a tissue or tumor.

公开(公告)号：US20210347850A1

公开(公告)日：2021-11-11

申请号：US17341098

申请日：2021-06-07

申请人： ImmunityBio, Inc.

发明人： Laurent H. Boissel ,  Hans G. Klingemann ,  Abhijit Dandapat ,  Himani Chinnapen

IPC分类号： C07K14/735 ,  A61P35/00 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  A61K39/395 ,  A61K45/06 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783

摘要： Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.

公开(公告)号：US20230272042A1

公开(公告)日：2023-08-31

申请号：US18179995

申请日：2023-03-07

申请人： ImmunityBio, Inc.

发明人： Laurent H. Boissel ,  Hans G. Klingemann ,  Abhijit Dandapat ,  Himani Chinnapen

IPC分类号： C07K14/735 ,  A61P35/00 ,  A61K35/17 ,  A61K38/17 ,  A61K38/20 ,  A61K39/395 ,  A61K45/06 ,  C07K14/54 ,  C07K14/55 ,  C07K14/705 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783

CPC分类号： C07K14/70535 ,  A61P35/00 ,  A61K35/17 ,  A61K38/1774 ,  A61K38/2013 ,  A61K38/2086 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/70517 ,  C07K14/70521 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/32 ,  C12N5/0646 ,  A61K2039/505

摘要： Recombinant NK cells, and especially recombinant NK-92 cells express a chimeric antigen receptor (CAR) having an intracellular domain of FcεRIγ. Notably, CAR constructs with an intracellular domain of FcεRIγ had a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR may be expressed from RNA and DNA, preferably as a tricistronic construct that further encodes CD16 and a cytokine to confer autocrine growth support. Advantageously, such constructs also enable high levels of transfection and expression of the recombinant proteins and provide a convenient selection marker to facilitate rapid production of recombinant NK/NK-92 cells.

公开(公告)号：US11813292B2

公开(公告)日：2023-11-14

申请号：US16966868

申请日：2019-03-11

申请人： ImmunityBio, Inc.

发明人： Patrick Soon-Shiong ,  Hans G Klingemann ,  Laurent H Boissel ,  Himani Chinnapen ,  Abhijit Dandapat

IPC分类号： A61K35/17 ,  A61K38/17

CPC分类号： A61K35/17 ,  A61K38/1774

摘要： The present application is directed to methods and compositions that are useful for reducing the number of myeloid-derived suppressor cells (MDSC), tumor associated macrophages (TAM), or both in a subject. The methods include administering an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or administering a modified T cell or NK-92 cell that expresses an antigen binding protein that binds to an antigen expressed by MDSC and/or TAM, or a combination of both, to a subject. For example, the antigen binding protein can bind to CD33 expressed by MDSC and/or TAM. The methods and compositions are useful for treating a disease associated with MDSC and/or TAM infiltration into a tissue or tumor.